Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

lets goooo!

Beware of misleading headlines and clickbait conclusions. Here is the synopsis: The sunscreen paradox: McGill University researchers warn of ‘false sense of security’ 👉 “Sunscreen is important, says Dr. Ivan Litvinov, but it is also the least effective way to protect your skin when compared to sun protective clothing and sun avoidance” 👨‍⚕️ 🔗mcgill.ca/newsroom/channels/…

"Stop treating energy as something to atone for. Energy is the master resource, the thing that buys us nearly every other good. The whole of human history is the story of harnessing ever more energy to improve our lives and to hold the lethal forces of nature at bay." The imperative is to accelerate abundant carbon-free energy (including the n-word). | How Europe Became the World Champion of Heat Deaths quillette.com/2026/06/24/how…

damn this is a devastating paper please take care of yourself, do you actually know how bad dying from cancer is? if you dont, consider yourself lucky get off your ass and take care of the only body you have

Nicotinamide mononucleotide stimulates the activity of bursting slow-oscillation neurons in the supramammillary nucleus and enhances REM sleep pmc.ncbi.nlm.nih.gov/article…

How much is due to damage and how much to epigenetic drift???

Researchers from across disciplines will gather this August to explore whether entropy offers a unifying framework for understanding aging. vist.ly/57cph #longevity #geroscience #entropy #aging #research

are you paying attention chad? the anti-aging and human enhancement arms race just went geopolitical - Russia committed $26B. Putin made longevity a Kremlin priority. organ printing, genetics, cryotherapy. - China published a 5-year national biotech plan. gene therapy, BCIs, AI drug discovery. genuine human firsts, not me-too drugs. - UAE launched a national longevity program backed by sovereign wealth. zero taxes. fastest clinical trial approvals in the world. - Singapore is funding longevity research at the state level and recruiting the world's best biotech founders. and the private sector is not waiting - Life Biosciences just injected the first reverse-aging drug into a human - NewLimit raised $435M from Peter Thiel's Founders Fund. Brian Armstrong's bet on age reprogramming is moving from lab to clinic. - Retro Biosciences raised $1.8B. Sam Altman's bet on adding 10 healthy years to human lifespan is scaling. - Isomorphic Labs raised $2.1B. Demis Hassabis betting AI designs drugs better than humans. - Neuralink has 21 implants in humans. Merge Labs launched with $252M. the BCI race is real. - Altos Labs. $3B from Bezos. cellular rejuvenation. the largest single longevity round ever. every major power and every serious founder on earth is pointing at the same problem the race has begun bio/acc

Two days ago, something happened that most of the world still doesn't know about. A human being received the first therapy in history designed to reverse cellular aging inside their body. Not slow it down. Not manage the symptoms. Actually reset the biological clock at the cellular level. @lifebiosciences — co-founded by Harvard geneticist @davidasinclair — announced on June 9 that the first patient was dosed in their Phase 1 clinical trial of ER-100. Let me explain what this actually is, because the implications extend far beyond the eye they're treating. Your DNA is mostly intact throughout your life. Think of it as hardware. What degrades is the epigenome — the layer of chemical instructions that tells your genes what to do and when. Over decades, those instructions get corrupted. Genes that should be active go silent. Genes that should be silent activate. Cells lose their identity and function. We call this aging. ER-100 uses three transcription factors — OCT4, SOX2, and KLF4 — to perform a partial epigenetic reset. These are the same factors that can reprogram any adult cell back into a stem cell. But they're not going that far. They're doing just enough to make damaged cells function like younger versions of themselves — without losing their identity. The delivery is elegant. A one-time injection into the eye. An oral pill acts as an on/off switch — doctors control exactly how long the reprogramming lasts. If anything goes wrong, they turn it off. This didn't come from nowhere. In 2020, Sinclair's team restored vision in old mice and mice with glaucoma using this approach. The paper made the cover of Nature. They moved to monkeys with optic nerve damage — and successfully restored function with no major safety issues. Now, two days ago: the first human. The trial is targeting glaucoma and NAION — a sudden "stroke of the eye" that causes devastating vision loss. Current treatments for both can only slow progression. Nothing reverses the damage. This therapy aims to regenerate damaged optic nerve cells by making them young again. As a cardiologist, here's why this keeps me up at night — in the best possible way. The eye is a safe, measurable starting point. But the platform technology isn't limited to the eye. If partial epigenetic reprogramming works safely in optic nerve cells, the same approach could theoretically be adapted for the brain, the spinal cord, the heart, the liver, the kidneys — any organ where cells lose function with age. We're not testing whether we can treat one disease. We're testing whether we can treat aging itself as a reversible biological process. For my entire career, cardiology has been magnificent at managing the downstream consequences of aging: high blood pressure, plaque buildup, heart failure, arrhythmias, stiffened arteries. We prescribe statins, antihypertensives, anticoagulants, and devices to manage what time does to the cardiovascular system. We're getting better every year. But what if the cells themselves could be reset? What if the cardiac muscle cells that lose contractile function with age could be epigenetically restored? What if the endothelial cells lining sixty thousand miles of blood vessels could be made to behave like they did decades earlier? That's not in a trial yet. But the foundational technology just entered a human body for the first time. And the companies racing in this space — Life Biosciences, Altos Labs, NewLimit — are backed by billions of dollars and some of the best scientists alive. Essential caveats — because I'm a physician, not a hype man. This is Phase 1. Roughly 18 patients. The primary goal is safety: does this cause harm? Is it tolerable? Efficacy data will come later. Many promising therapies have failed in the gap between animal models and human reality. Gene therapy carries risks — immune reactions, off-target effects, unintended cellular behavior. The oral on/off switch is a critical safety feature, but this is still the earliest possible stage of testing. No one is reversing aging tomorrow. No one is living to 200 next year. But a line was crossed two days ago that cannot be uncrossed. For the first time in human history, someone received a therapy specifically designed to make damaged cells young again inside a living person. From impossible in theory to proven in mice to tested in monkeys to injected into a human being — in six years. I've spent twenty years treating the consequences of aging. I've held hearts that were failing because time had degraded the cells beyond recovery. I've watched patients lose vision, cognition, mobility, and independence — and told them there was nothing I could do to reverse what time had taken. This week, the conversation began to change. Gene editing to permanently lower cholesterol. Personalized mRNA vaccines to hunt cancer. GLP-1 drugs rewiring metabolism, reducing depression, and cutting cancer metastasis. And now — partial cellular reprogramming to reverse aging at the epigenetic level. I said months ago on this platform that our children may live past 100 — not frail, but strong and vibrant. The evidence keeps building that this isn't optimism. It's a timeline.

Generation Z has the lowest levels of interpersonal trust of any generation we've ever polled. And although the data is time limited, the velocity of their decline in trust already far exceeds any previous generation.

Russia just committed $26 billion to anti-aging research and made longevity a national priority. Welcome to the longevity arms race!